NAS
CPRX

Nykredit A/S’s Catalyst Pharmaceutical CPRX Stock Holding History

Nykredit A/S’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.4K Buy
+3,163
New +$93.3K ﹤0.01% 1316

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Nykredit A/S's CPRX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 3,163 shares worth $99.4K. The stake represents ﹤0.01% of the portfolio and ranks #1316 among its holdings.

296 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Nykredit A/S held 3,163 shares of Catalyst Pharmaceutical worth $99.4K as of Q2 2026.
  • Catalyst Pharmaceutical was a new Nykredit A/S position in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1316 holding.
  • 296 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.